Related Experiment Video
Updated: Jun 27, 2026

Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
Purification and functional characterization of gag-spike virus-like particles: Process optimization for efficient
Anahita Bakhshizadeh Gashti1, Mehul Patel1, Parminder Singh Chahal1
1Bioprocess Engineering Department, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, QC, Canada.
This study developed a scalable purification process for SARS-CoV-2 Spike-displaying virus-like particles (VLPs), ensuring their structural integrity and functionality for vaccine applications.
Area of Science:
- Biotechnology
- Vaccine Development
- Protein Engineering
Background:
- Virus-like particles (VLPs) displaying the SARS-CoV-2 Spike protein are a promising vaccine platform.
- Efficient and scalable purification is crucial for VLP-based vaccine production.
Purpose of the Study:
- To develop and optimize a scalable downstream purification process for Gag-Spike VLPs.
- To ensure the structural integrity and functional immunogenicity of purified VLPs.
Main Methods:
- Optimization of tangential flow filtration (TFF) parameters (TMP, shear rates).
- Evaluation of various chromatographic resins (e.g., SepFast DUO, CaptoCore, CIMmultus QA, HiTrap Q).
- Sequential purification strategies and sterile filtration.
Main Results:
- Maximized permeate flux during TFF while maintaining VLP integrity.
- Identified effective chromatographic methods for impurity removal (host cell proteins, DNA).
- Confirmed VLP purity, size homogeneity, and retention of functional Spike proteins via SDS-PAGE, DLS, and flow-virometry.
Conclusions:
- A robust and scalable purification strategy for Gag-Spike VLPs was established.
- The process preserves VLP structural and functional properties essential for vaccine development.
- This methodology supports the advancement of VLP-based vaccines against SARS-CoV-2.
More Related Videos
08:40Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Published on: March 1, 2019
05:15Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022